What Is SR9009 Studied For? Research Areas, Per the Literature

SR9009 is a synthetic small molecule described in the published literature as an agonist of the REV-ERB nuclear receptors, and essentially all of the research summarised below was performed in cell culture or in rodents. SR9009 is not approved by the FDA as a medicine for any condition. This page is not guidance. This page is for educational purposes only and is not medical advice; consult a licensed physician with questions about any compound or health condition.

The sections that follow are organised by research area. Each statement identifies the study type (in vitro, animal, or review) and the model that was studied, with the PubMed citation in the same passage. Background on the molecule itself is collected on the SR9009 learn hub.

What SR9009 Is, in Research Terms

REV-ERBα and REV-ERBβ are nuclear receptors that act as transcriptional repressors inside the molecular circadian clock. Because they repress gene programmes involved in metabolism, innate immunity and tissue remodelling, laboratory groups have used REV-ERB agonists as pharmacological probes to ask what happens when those programmes are suppressed. In most of the papers cited here, SR9009 served as a tool compound to test a receptor hypothesis rather than as a candidate therapy, and the authors generally framed results as mechanism rather than as clinical findings. A 2024 review in Frontiers in Immunology described the disrupted molecular circadian clock of monocytes and macrophages in allergic inflammation and surveyed clock-targeting pharmacology as an experimental strategy (PMID 38863703).

Neuroinflammation and Microglia

One of the most cited research areas is central nervous system inflammation. A 2019 mouse study in PNAS reported that genetic deletion of Rev-erbα in mice produced spontaneous glial activation, hippocampal oxidative damage and increased inflammatory gene expression, and that pharmacological REV-ERB agonism suppressed inflammatory activation in microglia (PMID 30792350). The study was genetic and pharmacological in design, in mice and primary glial cultures, and did not involve human participants.

A separate 2021 study examined spinal microglia and reported that stimulation of REV-ERB nuclear receptors suppressed inflammatory responses in those cells (PMID 34710533). That work used cultured rodent microglia, so the finding describes cellular signalling rather than a demonstrated outcome in an intact organism, let alone in people.

Gut Inflammation and Experimental Colitis

Researchers have also asked whether the colonic clock influences intestinal inflammation. A 2018 mouse study in Nature Communications reported that REV-ERBα integrates the colon clock with experimental colitis through regulation of the NF-κB/NLRP3 axis, and that manipulating REV-ERBα altered inflammasome-driven colitis severity in mice (PMID 30315268). This was a chemically induced rodent colitis model, which is standard for mechanism work but is not a substitute for a controlled trial in patients with inflammatory bowel disease.

Autoimmunity and T Helper 17 Cells

Adaptive immunity has been a further focus. A 2018 study in Cell Reports reported that REV-ERBα regulates T_H17 cell development and influences autoimmunity in mouse models (PMID 30590045). The study combined mouse genetics with pharmacological REV-ERB activation in T cell differentiation experiments. No human autoimmune disease trial of SR9009 appears in the verified literature set used for this page.

Cholesterol and Lipid Gene Regulation

Metabolic gene regulation is the area most often invoked when SR9009 is discussed outside of science. A 2017 paper in Biochemical Pharmacology examined REV-ERB regulation of cholesterologenesis and reported that REV-ERB activity shapes expression of cholesterol biosynthesis genes, with experiments spanning cell models and mice (PMID 28213272). The study described transcriptional control of a biosynthetic pathway; it did not report clinical lipid outcomes, cardiovascular endpoints or any human dosing.

Cardiac Fibroblasts and Collagen Homeostasis

Connective tissue biology forms a smaller but notable cluster. A 2022 study in Frontiers in Pharmacology reported that REV-ERB is essential in cardiac fibroblast homeostasis, using cellular and mouse experiments in which REV-ERB activity was altered genetically and pharmacologically (PMID 36386186). The authors framed REV-ERB as necessary for normal fibroblast behaviour, which is a point of caution as much as a therapeutic hypothesis, since suppressing a receptor that maintains homeostasis can cut in either direction.

Adjacent to that, a 2020 study in Nature Cell Biology reported that circadian control of the secretory pathway maintains collagen homeostasis in mouse tissue, and that clock disruption altered collagen handling (PMID 31907414). That work is background on why clock-targeting molecules are of interest in connective tissue research rather than a direct test of SR9009 as a treatment.

Bone Biology and Alveolar Bone Loss

A 2025 study in the Journal of Dental Research reported that REV-ERBα inhibits osteoclastogenesis and protects against alveolar bone loss, combining osteoclast differentiation assays with a mouse periodontal bone loss model (PMID 39629951). The study positioned REV-ERBα as a negative regulator of bone resorbing cell formation. As with the other areas here, the evidence is preclinical, and no periodontal trial in humans is included in this citation set.

Liver Ischemia Reperfusion Injury

A 2020 study in Biochemical and Biophysical Research Communications reported that Rev-erbα regulates hepatic ischemia reperfusion injury in mice, linking receptor activity to the degree of liver damage in that surgical rodent model (PMID 32819599). Ischemia reperfusion models are used to study acute organ injury mechanisms; the study did not examine chronic liver disease or any human outcome.

Virology: HIV-1 Replication in Cell Systems

A 2020 study in Scientific Reports reported that pharmacological activation of the circadian component REV-ERB inhibited HIV-1 replication in cell culture systems (PMID 32764708). The work was conducted in vitro using infected cell models, and the authors described a transcriptional mechanism. In vitro antiviral activity is a very early signal and has not, in this citation set, been followed by clinical evaluation.

Pain Models

A 2025 study in The Journal of Neuroscience reported that the circadian clock component REV-ERB is an analgesic target for cancer-induced tactile pain hypersensitivity in a rodent model (PMID 40268481). Behavioural pain testing in mice measured tactile sensitivity thresholds. The study described a target hypothesis in animals; it is not evidence of analgesia in people.

Research Areas at a Glance

Searched Uses With Weak or Absent Evidence

Several applications are frequently associated with SR9009 in non-scientific writing, including endurance capacity, fat loss, body composition change and general metabolic enhancement in healthy adults. None of the verified papers summarised on this page measured exercise performance, fat mass or body composition in humans. The metabolic work that does exist in this set is transcriptional: the 2017 cholesterologenesis paper examined regulation of cholesterol biosynthesis gene expression in cell models and mice (PMID 28213272), which is a mechanistic observation and not a demonstration of a physique or performance outcome.

Equally, the inflammation, bone, liver, antiviral and pain findings described above were reported in rodents or cultured cells, including the colitis model (PMID 30315268) and the cancer pain model (PMID 40268481). Preclinical findings commonly fail to reproduce in human trials, and the absence of human data in this citation set is itself the most important fact about the evidence base.

Safety and Adverse Events: What Studies Report

The verified literature set contains no human safety or tolerability study of SR9009, so no human adverse event profile can be described from it. What the preclinical work does suggest is that REV-ERB is not an idle target: the 2022 cardiac study reported that REV-ERB is essential in cardiac fibroblast homeostasis, meaning that normal cardiac fibroblast function depended on intact receptor activity (PMID 36386186). Similarly, the 2019 mouse work reported that loss of Rev-erbα drove spontaneous neuroinflammation and oxidative damage (PMID 30792350), and the 2020 collagen study reported that clock disruption altered collagen homeostasis in mouse tissue (PMID 31907414). Receptors embedded in circadian, immune and structural pathways are, by definition, difficult to modulate without broad downstream consequences, and the cited studies did not resolve long term safety in any species.

Regulatory Status and Scope of This Page

SR9009 appears in the literature as an experimental compound used in laboratory research. It is not an approved pharmaceutical product, and the studies cited here are mechanistic and preclinical rather than registrational. SR9009 is not approved by the FDA as a medicine for any condition. This page is not guidance. This page summarises what published studies reported, including the study type and model in each case, so that readers can see where the evidence sits. This page is for educational purposes only and is not medical advice; consult a licensed physician with questions about any compound or health condition.

References

• Circadian clock protein Rev-erbα regulates neuroinflammation (Proceedings of the National Academy of Sciences of the United States of America, 2019)
• The disrupted molecular circadian clock of monocytes and macrophages in allergic inflammation (Frontiers in Immunology, 2024)
• Rev-erb regulation of cholesterologenesis (Biochemical Pharmacology, 2017)
• REV-ERBα integrates colon clock with experimental colitis through regulation of NF-κB/NLRP3 axis (Nature Communications, 2018)
• REV-ERB is essential in cardiac fibroblasts homeostasis (Frontiers in Pharmacology, 2022)
• REV-ERBα Inhibits Osteoclastogenesis and Protects against Alveolar Bone Loss (Journal of Dental Research, 2025)
• Rev-erbα regulates hepatic ischemia-reperfusion injury in mice (Biochemical and Biophysical Research Communications, 2020)
• Circadian control of the secretory pathway maintains collagen homeostasis (Nature Cell Biology, 2020)
• REV-ERBα Regulates T(H)17 Cell Development and Autoimmunity (Cell Reports, 2018)
• Stimulation of nuclear receptor REV-ERBs suppresses inflammatory responses in spinal microglia (Neurochemistry International, 2021)
• Pharmacological activation of the circadian component REV-ERB inhibits HIV-1 replication (Scientific Reports, 2020)
• The Circadian Clock Component REV-ERB Is an Analgesic Target for Cancer-Induced Tactile Pain Hypersensitivity (The Journal of Neuroscience, 2025)